QTRX vs TMO
QTRX: Quanterix develops ultra-sensitive protein detection and spatial tissue analysis platforms for biomarker discovery and early disease diagnostics, with recent FDA breakthrough designation for an Alzheimer's blood test. TMO: Thermo Fisher Scientific is a leading global provider of mission-critical laboratory equipment, analytical instrumentation, and scientific services for research and clinical markets.
Side-by-side fundamentals
| Metric | QTRX | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.84 | $526.46 | |
| Market cap as of 2026-07-23 | $181M | $194.1B | |
| P/E as of 2026-07-23 | n/a | 28.36 | |
| PEG as of 2026-07-23 | -0.02 | 2.89 | QTRX lower |
| Net margin as of 2026-07-23 | -71.9% | +15.2% | TMO higher |
| Gross margin as of 2026-07-23 | +44.2% | +40.9% | QTRX higher |
| Operating margin as of 2026-07-23 | -96.9% | +17.5% | TMO higher |
| ROE as of 2026-07-23 | -35.2% | +13.2% | TMO higher |
| ROA as of 2026-07-23 | -26.0% | +6.4% | TMO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.83 | QTRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.8% | +5.4% | QTRX higher |
| Revenue CAGR (3y) SEC XBRL | +9.6% | -0.3% | QTRX higher |
| Dividend yield as of 2026-07-23 | n/a | +0.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.04 | 0.86 | |
| 1-year return as of 2026-07-22 close | -23.4% | +23.1% | TMO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.